Prophylactic Strategies to Control Chikungunya Virus Infection

Overview

Journal Virus Genes

Specialties Microbiology
Molecular Biology

Date 2021 Feb 16

PMID 33590406

Citations 6

Authors

Friederike I L Hucke

Malena Bestehorn-Willmann

Joachim J Bugert

Affiliations

Soon will be listed here.

Abstract

Chikungunya virus (CHIKV) is a (re)emerging arbovirus and the causative agent of chikungunya fever. In recent years, CHIKV was responsible for a series of outbreaks, some of which had serious economic and public health impacts in the affected regions. So far, no CHIKV-specific antiviral therapy or vaccine has been approved. This review gives a brief summary on CHIKV epidemiology, spread, infection and diagnosis. It furthermore deals with the strategies against emerging diseases, drug development and the possibilities of testing antivirals against CHIKV in vitro and in vivo. With our review, we hope to provide the latest information on CHIKV, disease manifestation, as well as on the current state of CHIKV vaccine development and post-exposure therapy.

Citing Articles

Comparative analysis of midgut bacterial communities in Chikungunya virus-infected and non-infected Aedes aegypti Thai laboratory strain mosquitoes.

Siriyasatien P, Intayot P, Chitcharoen S, Sutthanont N, Boonserm R, Ampol R Sci Rep. 2024; 14(1):10814.

PMID: 38734695 PMC: 11088667. DOI: 10.1038/s41598-024-61027-0.

Development of Therapeutic Monoclonal Antibodies for Emerging Arbovirus Infections.

Ormundo L, Barreto C, Tsuruta L Viruses. 2023; 15(11).

PMID: 38005854 PMC: 10675117. DOI: 10.3390/v15112177.

Antiviral activity of myricetin glycosylated compounds isolated from against chikungunya virus.

Munoz A, Cuellar A, Arevalo G, Santamaria B, Rodriguez A, Buendia-Atencio C EXCLI J. 2023; 22:716-731.

PMID: 37662709 PMC: 10471840. DOI: 10.17179/excli2023-6242.

Equine Polyclonal Antibodies Prevent Acute Chikungunya Virus Infection in Mice.

Barker D, Han X, Wang E, Dagley A, Anderson D, Jha A Viruses. 2023; 15(7).

PMID: 37515166 PMC: 10384969. DOI: 10.3390/v15071479.

CHIKV strains Brazil (wt) and Ross (lab-adapted) differ with regard to cell host range and antiviral sensitivity and show CPE in human glioblastoma cell lines U138 and U251.

Hucke F, Bestehorn-Willmann M, Bassetto M, Brancale A, Zanetta P, Bugert J Virus Genes. 2022; 58(3):188-202.

PMID: 35347588 PMC: 8960095. DOI: 10.1007/s11262-022-01892-x.

References

Akahata W, Yang Z, Andersen H, Sun S, Holdaway H, Kong W . A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med. 2010; 16(3):334-8. PMC: 2834826. DOI: 10.1038/nm.2105. View

Smith S, Silva L, Fox J, Flyak A, Kose N, Sapparapu G . Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus. Cell Host Microbe. 2015; 18(1):86-95. PMC: 4501771. DOI: 10.1016/j.chom.2015.06.009. View

Couderc T, Khandoudi N, Grandadam M, Visse C, Gangneux N, Bagot S . Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis. 2009; 200(4):516-23. PMC: 7109959. DOI: 10.1086/600381. View

Alphey L, Benedict M, Bellini R, Clark G, Dame D, Service M . Sterile-insect methods for control of mosquito-borne diseases: an analysis. Vector Borne Zoonotic Dis. 2009; 10(3):295-311. PMC: 2946175. DOI: 10.1089/vbz.2009.0014. View

Wedell N, Price T, Lindholm A . Gene drive: progress and prospects. Proc Biol Sci. 2019; 286(1917):20192709. PMC: 6939923. DOI: 10.1098/rspb.2019.2709. View

Wichit S, Diop F, Hamel R, Talignani L, Ferraris P, Cornelie S . Aedes Aegypti saliva enhances chikungunya virus replication in human skin fibroblasts via inhibition of the type I interferon signaling pathway. Infect Genet Evol. 2017; 55:68-70. DOI: 10.1016/j.meegid.2017.08.032. View

Pal P, Fox J, Hawman D, Huang Y, Messaoudi I, Kreklywich C . Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. J Virol. 2014; 88(15):8213-26. PMC: 4135940. DOI: 10.1128/JVI.01032-14. View

Goo L, Dowd K, Lin T, Mascola J, Graham B, Ledgerwood J . A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes. J Infect Dis. 2016; 214(10):1487-1491. PMC: 5091377. DOI: 10.1093/infdis/jiw431. View

Rezza G, Weaver S . Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development. PLoS Negl Trop Dis. 2019; 13(1):e0006919. PMC: 6336248. DOI: 10.1371/journal.pntd.0006919. View

10.

Khan M, Dhanwani R, Patro I, Rao P, Parida M . Cellular IMPDH enzyme activity is a potential target for the inhibition of Chikungunya virus replication and virus induced apoptosis in cultured mammalian cells. Antiviral Res. 2010; 89(1):1-8. DOI: 10.1016/j.antiviral.2010.10.009. View

11.

Ramsauer K, Schwameis M, Firbas C, Mullner M, Putnak R, Thomas S . Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis. 2015; 15(5):519-27. DOI: 10.1016/S1473-3099(15)70043-5. View

12.

Rathore A, Haystead T, Das P, Merits A, Ng M, Vasudevan S . Chikungunya virus nsP3 & nsP4 interacts with HSP-90 to promote virus replication: HSP-90 inhibitors reduce CHIKV infection and inflammation in vivo. Antiviral Res. 2014; 103:7-16. DOI: 10.1016/j.antiviral.2013.12.010. View

13.

Zhang R, Kim A, Fox J, Nair S, Basore K, Klimstra W . Mxra8 is a receptor for multiple arthritogenic alphaviruses. Nature. 2018; 557(7706):570-574. PMC: 5970976. DOI: 10.1038/s41586-018-0121-3. View

14.

Jacobsen S, Patel P, Schmidt-Chanasit J, Leparc-Goffart I, Teichmann A, Zeller H . External quality assessment studies for laboratory performance of molecular and serological diagnosis of Chikungunya virus infection. J Clin Virol. 2016; 76:55-65. DOI: 10.1016/j.jcv.2016.01.008. View

15.

Cerny T, Schwarz M, Schwarz U, Lemant J, Gerardin P, Keller E . The Range of Neurological Complications in Chikungunya Fever. Neurocrit Care. 2017; 27(3):447-457. DOI: 10.1007/s12028-017-0413-8. View

16.

Parashar D, Paingankar M, Kumar S, Gokhale M, Sudeep A, Shinde S . Administration of E2 and NS1 siRNAs inhibit chikungunya virus replication in vitro and protects mice infected with the virus. PLoS Negl Trop Dis. 2013; 7(9):e2405. PMC: 3764232. DOI: 10.1371/journal.pntd.0002405. View

17.

Khan A, Morita K, Parquet M, Hasebe F, Mathenge E, Igarashi A . Complete nucleotide sequence of chikungunya virus and evidence for an internal polyadenylation site. J Gen Virol. 2002; 83(Pt 12):3075-3084. DOI: 10.1099/0022-1317-83-12-3075. View

18.

Wilson A, Courtenay O, Kelly-Hope L, Scott T, Takken W, Torr S . The importance of vector control for the control and elimination of vector-borne diseases. PLoS Negl Trop Dis. 2020; 14(1):e0007831. PMC: 6964823. DOI: 10.1371/journal.pntd.0007831. View

19.

Bugert J, Hucke F, Zanetta P, Bassetto M, Brancale A . Antivirals in medical biodefense. Virus Genes. 2020; 56(2):150-167. PMC: 7089181. DOI: 10.1007/s11262-020-01737-5. View

20.

Strauss J, Strauss E . The alphaviruses: gene expression, replication, and evolution. Microbiol Rev. 1994; 58(3):491-562. PMC: 372977. DOI: 10.1128/mr.58.3.491-562.1994. View